Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dasatinib is a multitargeted inhibitor of ABL, the SRC family, and other tyrosine kinases. We sought to evaluate the effects of this drug on cell proliferation, centrosomes, mitotic spindles, and cell cycle progression in vitro and in vivo. DESIGN AND METHODS: Human dermal fibroblasts, Chinese hamster cells, human osteosarcoma cells, and blood and bone marrow mononuclear cells from 32 patients with chronic myeloid leukemia, gastrointestinal stromal tumor, and systemic mastocytosis as well as from six healthy individuals were investigated. The effects of dasatinib were compared with those of the ABL inhibitors imatinib and nilotinib, the SRC inhibitor PP2, and the ABL/LYN inhibitor INNO-406. RESULTS: Dasatinib induced G(1) phase arrest in all cell lines and this was associated with a decline in cyclin D1 levels. In vitro, centrosomal aberrations, a decrease of mitotic spindles, and G(1) phase arrest were observed. In patients, centrosome alterations were found in a median of 17% (range, 10-22%) of cells with a decrease of spindles in 8/18 patients. In comparison, imatinib, nilotinib and PP2 led to centrosome aberrations without G(1) phase arrest. INNO-406 was associated with centrosome aberrations and cell cycle arrest in G(1) phase. CONCLUSIONS: Dasatinib blocks the G(1)/S transition and inhibits cell growth. It induces centrosomal aberrations and a decrease of mitotic spindles. The effects suggest an involvement of SRC and ABL inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 1×
“Patients on dasatinib therapy (CML, n=17; GIST, n=1) 18 Age at start of dasatinib, years 57 (26-75) % male 50 Previous therapy 18 (100) Imatinib 4 (22) Imatinib, HU 1 (6) Imatinib, IFN 4 (22) Imatinib, HU, IFN 6 (33) Imatinib, HU, IFN, AraC 2 (11) Follow-up of all patients after diagnosis, months 75 (10-198) Follow-up…”
BackgroundYeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · cited 1×
“Patients on dasatinib therapy (CML, n=17; GIST, n=1) 18 Age at start of dasatinib, years 57 (26-75) % male 50 Previous therapy 18 (100) Imatinib 4 (22) Imatinib, HU 1 (6) Imatinib, IFN 4 (22) Imatinib, HU, IFN 6 (33) Imatinib, HU, IFN, AraC 2 (11) Follow-up of all patients after diagnosis, months 75 (10-198) Follow-up…”
Background
Cited by
A Clinical Overview of Centrosome Amplification in Human Cancers
Chan, J. Y. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.1122 · Cited by 379
Stepanenko, A. A., & Dmitrenko, V. V. (2015) · Gene · doi:10.1016/j.gene.2015.08.009 · Cited by 315
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis
Ustun, C., DeRemer, D. L., & Akin, C. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.05.006 · Cited by 102
Lindauer, M., & Hochhaus, A. (2010) · Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_7 · Cited by 57
Self-citationImpact of BCR::ABL1 single nucleotide variants on asciminib efficacy
Innes, A. J., Hayden, C., Orovboni, V., Claudiani, S., Fernando, F., Khan, A., Rees, D., Byrne, J., Gallipoli, P., Francis, S., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02411-7 · Cited by 13
Metadata
- Authors
- Fabarius, A., Giehl, M., Rebacz, B., Kramer, A., Frank, O., Haferlach, C., Duesberg, P., Hehlmann, R., Seifarth, W., & Hochhaus, A.
- Venue
- Haematologica
- Published
- 2008-08-01
- Volume
- 93
- Issue
- 8
- Pages
- 1145-1154
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2118978570
- Cited by
- 38
- References
- 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. https://app.cochat.ai/papers/10.3324/haematol.12793
- The paper
- Fabarius, A., Giehl, M., Rebacz, B., Kramer, A., Frank, O., Haferlach, C., Duesberg, P., Hehlmann, R., Seifarth, W., & Hochhaus, A. (2008). Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica. https://doi.org/10.3324/haematol.12793
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.